Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs

Future Med Chem. 2020 Mar;12(6):533-561. doi: 10.4155/fmc-2019-0312. Epub 2020 Feb 12.

Abstract

Acetyl-CoA carboxylase (ACC), a critical enzyme in the regulation of fatty acid synthesis and metabolism, has emerged as an attractive target for a plethora of emerging diseases, such as diabetes mellitus, nonalcoholic fatty liver disease, cancer, bacterial infections and so on. With decades of efforts in medicinal chemistry, significant progress has been made toward the design and discovery of a considerable number of inhibitors of this enzyme. In this review, we not only clarify the role of ACC in emerging diseases, but also summarize recent developments of potent ACC inhibitors and discuss their molecular mechanisms of action and potentials as novel drugs as well as future perspectives toward the design and discovery of novel ACC inhibitors.

Keywords: acetyl-CoA carboxylase; bacterial infections; cancer; crystal structure; fatty acid; metabolic diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acetyl-CoA Carboxylase / antagonists & inhibitors*
  • Acetyl-CoA Carboxylase / chemistry
  • Acetyl-CoA Carboxylase / metabolism
  • Animals
  • Drug Development
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Models, Molecular

Substances

  • Enzyme Inhibitors
  • Acetyl-CoA Carboxylase